SCHEMBL7182430

SCHEMBL7182430

O=C(Pc1ccc(OCc2ccccc2)cc1OCc1ccccc1)c1c(C(F)(F)F)cccc1C(F)(F)F.[LiH]

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 5/20 0.48
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
RXRG P48443 1/20 0.48
AR P10275 1/20 0.46
MAOB P27338 3/20 0.43
FFAR1 O14842 3/20 0.42
FFAR4 Q5NUL3 1/20 0.42
NR4A2 P43354 2/20 0.41
PPARG P37231 2/20 0.41
PTGES O14684 1/20 0.41
ALOX5 P09917 1/20 0.41
PSEN1 P49768 1/20 0.41
NR1H2 P55055 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
NR1H3 Q13133 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7182438 0.98 MRGPRX4 (0.48) MRGPRX4RXRARXRBRXRGAR
SCHEMBL7177524 0.88 MRGPRX4 (0.45) MRGPRX4RXRARXRBRXRGAR
SCHEMBL7185527 0.87 MRGPRX4 (0.50) MRGPRX4RXRARXRBRXRGAR
SCHEMBL7175449 0.84 HPGD (0.46) MRGPRX4RXRARXRBRXRGMAOB
SCHEMBL7177769 0.83 MAOB (0.48) RXRARXRBRXRGMAOBFFAR1
SCHEMBL7184698 0.83 KDM4E (0.42) MRGPRX4RXRARXRBRXRGAR
SCHEMBL7182230 0.83 RXRA (0.47) MRGPRX4RXRARXRBRXRGMAOB
SCHEMBL7187430 0.82 L3MBTL1 (0.49) MRGPRX4RXRAMAOBFFAR1PPARA
Lithium SCHEMBL7175455 0.82 HPGD (0.46) MRGPRX4RXRARXRBRXRGMAOB
SCHEMBL7182872 0.81 THRA (0.41) MRGPRX4PPARGPTGESALOX5PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MRGPRX4 3913/4885RXRA 2745/4885RXRB 3027/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MRGPRX4 4163/4885RXRA 2809/4885RXRB 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.